Cantel Medical Corp.'s Medivators Group Gains FDA 510(k) Approval For Its Advantage(TM) Plus Endoscope Reprocessing System
February 27 2009 - 11:57AM
PR Newswire (US)
LITTLE FALLS, N.J., Feb. 27 /PRNewswire-FirstCall/ -- CANTEL
MEDICAL CORP. (NYSE:CMN) announced today that the FDA has cleared
its Medivators Advantage Plus Endoscope Reprocessing System and new
Rapicide(R) PA High Level Disinfectant for sale in the United
States. The Advantage Plus System, with its accompanying new
chemistry, represents the latest in a long line of "state of the
art", innovative reprocessing technologies that Medivators has been
delivering to hospitals and stand-alone GI centers for over 20
years. Andrew Krakauer, Cantel Medical's President stated, "We are
very pleased to have broadened our regulatory approvals and can now
sell the full Advantage Series in the United States. The Advantage
Plus, together with its environmentally friendly Rapicide PA
chemistry, brings a new, fully integrated and compliant dimension
to busy endoscopy centers and is now available worldwide. We
believe that this system should rapidly become the new standard of
excellence for safety and efficacy, as well as user friendly
operation." Cantel Medical Corp. is a leading provider of infection
prevention and control products in the healthcare market. Our
products include specialized medical device reprocessing systems
for renal dialysis and endoscopy, dialysate concentrates and other
dialysis supplies, disposable infection control products primarily
for the dental industry, water purification equipment, sterilants,
disinfectants and cleaners, hollow fiber membrane filtration and
separation products for medical and non-medical applications, and
specialty packaging for infectious and biological specimens. We
also provide technical maintenance for our products and offer
compliance training services for the transport of infectious and
biological specimens. For further information, visit the Cantel
website at http://www.cantelmedical.com/. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
involve a number of risks and uncertainties, including, without
limitation, the risks detailed in Cantel's filings and reports with
the Securities and Exchange Commission. Such forward-looking
statements are only predictions, and actual events or results may
differ materially from those projected or anticipated. DATASOURCE:
Cantel Medical Corp. CONTACT: Andrew A. Krakauer, President of
Cantel Medical Corp., +1-973-890-7220; or Richard E. Moyer of
Cameron Associates, Inc., +1-212-554-5466, Web Site:
http://www.cantelmedical.com/
Copyright
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024